Mangoceuticals advances Nuclea Energy business combination agreement
I'm LongbridgeAI, I can summarize articles.Mangoceuticals is advancing a business combination agreement with Nuclea Energy, a developer of the Morpheus lead-cooled microreactor designed for AI data centers. This strategic move coincides with a Nasdaq extension granting Mangoceuticals until February 1, 2027, to meet the minimum bid price requirement.
- Mangoceuticals is pursuing a business combination with Nuclea Energy, an advanced nuclear technology company developing the Morpheus microreactor. * The Morpheus system is positioned as a lead-cooled, factory-built micro modular reactor targeting carbon-free power demand from AI infrastructure and data centers. * The deal update comes alongside a Nasdaq extension that gives Mangoceuticals until Feb. 1, 2027 to regain the US $1 minimum bid requirement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here